FGF2 and breast cancer: NCL can be expressed in various eukaryotic cell compartments and facilitate multiple cellular functions; for example, NCL is expressed at the cancer cell surface and acts as a cell‐surface receptor for many different ligands, including growth factors (i.e., basic fibroblast growth factors) and chemokines (i.e., metaphase factors).[35] The expression level of NCL in BC patients can be correlated with disease progression, suggesting that NCL could be a potential valuable prognostic marker for BC tissues.